In addition, CBP inhibitor therapy increases β-catenin binding to P300, which mediates cell differentiation, and causes P53/P21-dependent senescence in BCR-ABL mutant CML cells [131]. Here, CREBBP is linked to chronic myelogenous leukemia, BCR-ABL1 positive.